1.2024 Korean Society of Myocardial Infarction/National Evidence-Based Healthcare Collaborating Agency Guideline for the Pharmacotherapy of Acute Coronary Syndromes
Hyun Kuk KIM ; Seungeun RYOO ; Seung Hun LEE ; Doyeon HWANG ; Ki Hong CHOI ; Jungeun PARK ; Hyeon-Jeong LEE ; Chang-Hwan YOON ; Jang Hoon LEE ; Joo-Yong HAHN ; Young Joon HONG ; Jin Yong HWANG ; Myung Ho JEONG ; Dong Ah PARK ; Chang-Wook NAM ; Weon KIM
Korean Circulation Journal 2024;54(12):767-793
Many countries have published clinical practice guidelines for appropriate clinical decisions, optimal treatment, and improved clinical outcomes in patients with acute coronary syndrome. Developing guidelines that are specifically tailored to the Korean environment is crucial, considering the treatment system, available medications and medical devices, racial differences, and level of language communication. In 2017, the Korean Society of Myocardial Infarction established a guideline development committee. However, at that time, it was not feasible to develop guidelines, owing to the lack of knowledge and experience in guideline development and the absence of methodology experts. In 2022, the National EvidenceBased Healthcare Collaborating Agency collaborated with a relevant academic association to develop internationally reliable guidelines, with strict adherence to the methodology for evidence-based guideline development. The first Korean acute coronary syndrome guideline starts from the 9 key questions for pharmacotherapy.
2.2024 Korean Society of Myocardial Infarction/National Evidence-Based Healthcare Collaborating Agency Guideline for the Pharmacotherapy of Acute Coronary Syndromes
Hyun Kuk KIM ; Seungeun RYOO ; Seung Hun LEE ; Doyeon HWANG ; Ki Hong CHOI ; Jungeun PARK ; Hyeon-Jeong LEE ; Chang-Hwan YOON ; Jang Hoon LEE ; Joo-Yong HAHN ; Young Joon HONG ; Jin Yong HWANG ; Myung Ho JEONG ; Dong Ah PARK ; Chang-Wook NAM ; Weon KIM
Korean Circulation Journal 2024;54(12):767-793
Many countries have published clinical practice guidelines for appropriate clinical decisions, optimal treatment, and improved clinical outcomes in patients with acute coronary syndrome. Developing guidelines that are specifically tailored to the Korean environment is crucial, considering the treatment system, available medications and medical devices, racial differences, and level of language communication. In 2017, the Korean Society of Myocardial Infarction established a guideline development committee. However, at that time, it was not feasible to develop guidelines, owing to the lack of knowledge and experience in guideline development and the absence of methodology experts. In 2022, the National EvidenceBased Healthcare Collaborating Agency collaborated with a relevant academic association to develop internationally reliable guidelines, with strict adherence to the methodology for evidence-based guideline development. The first Korean acute coronary syndrome guideline starts from the 9 key questions for pharmacotherapy.
3.2024 Korean Society of Myocardial Infarction/National Evidence-Based Healthcare Collaborating Agency Guideline for the Pharmacotherapy of Acute Coronary Syndromes
Hyun Kuk KIM ; Seungeun RYOO ; Seung Hun LEE ; Doyeon HWANG ; Ki Hong CHOI ; Jungeun PARK ; Hyeon-Jeong LEE ; Chang-Hwan YOON ; Jang Hoon LEE ; Joo-Yong HAHN ; Young Joon HONG ; Jin Yong HWANG ; Myung Ho JEONG ; Dong Ah PARK ; Chang-Wook NAM ; Weon KIM
Korean Circulation Journal 2024;54(12):767-793
Many countries have published clinical practice guidelines for appropriate clinical decisions, optimal treatment, and improved clinical outcomes in patients with acute coronary syndrome. Developing guidelines that are specifically tailored to the Korean environment is crucial, considering the treatment system, available medications and medical devices, racial differences, and level of language communication. In 2017, the Korean Society of Myocardial Infarction established a guideline development committee. However, at that time, it was not feasible to develop guidelines, owing to the lack of knowledge and experience in guideline development and the absence of methodology experts. In 2022, the National EvidenceBased Healthcare Collaborating Agency collaborated with a relevant academic association to develop internationally reliable guidelines, with strict adherence to the methodology for evidence-based guideline development. The first Korean acute coronary syndrome guideline starts from the 9 key questions for pharmacotherapy.
4.2024 Korean Society of Myocardial Infarction/National Evidence-Based Healthcare Collaborating Agency Guideline for the Pharmacotherapy of Acute Coronary Syndromes
Hyun Kuk KIM ; Seungeun RYOO ; Seung Hun LEE ; Doyeon HWANG ; Ki Hong CHOI ; Jungeun PARK ; Hyeon-Jeong LEE ; Chang-Hwan YOON ; Jang Hoon LEE ; Joo-Yong HAHN ; Young Joon HONG ; Jin Yong HWANG ; Myung Ho JEONG ; Dong Ah PARK ; Chang-Wook NAM ; Weon KIM
Korean Circulation Journal 2024;54(12):767-793
Many countries have published clinical practice guidelines for appropriate clinical decisions, optimal treatment, and improved clinical outcomes in patients with acute coronary syndrome. Developing guidelines that are specifically tailored to the Korean environment is crucial, considering the treatment system, available medications and medical devices, racial differences, and level of language communication. In 2017, the Korean Society of Myocardial Infarction established a guideline development committee. However, at that time, it was not feasible to develop guidelines, owing to the lack of knowledge and experience in guideline development and the absence of methodology experts. In 2022, the National EvidenceBased Healthcare Collaborating Agency collaborated with a relevant academic association to develop internationally reliable guidelines, with strict adherence to the methodology for evidence-based guideline development. The first Korean acute coronary syndrome guideline starts from the 9 key questions for pharmacotherapy.
5.Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Soo-Young NA ; Chang Hwan CHOI ; Eun Mi SONG ; Ki Bae BANG ; Sang Hyoung PARK ; Eun Soo KIM ; Jae Jun PARK ; Bora KEUM ; Chang Kyun LEE ; Bo-In LEE ; Seung-Bum RYOO ; Seong-Joon KOH ; Miyoung CHOI ; Joo Sung KIM ;
Intestinal Research 2023;21(1):61-87
Ulcerative colitis (UC), a relapsing-remitting chronic inflammatory bowel disease (IBD), has a variable natural course but potentially severe disease course. Since the development of anti-tumor necrosis factor (TNF) agents has changed the natural disease course of moderate-to-severe UC, therapeutic options for patients who failed conventional treatments are expanding rapidly. IBD clinical trials have demonstrated the potential efficacy and safety of novel biologics such as anti-integrin α4β7 and anti-interleukin-12/23 monoclonal antibodies and small molecules such as a Janus kinase inhibitor. Anti-TNF biosimilars also have been approved and are widely used in IBD patients. Wise drug choices should be made considering evidence-based efficacy and safety. However, the best position of these drugs remains several questions, with limited data from direct comparative trials. In addition, there are still concerns to be elucidated on the effect of therapeutic drug monitoring and combination therapy with immunomodulators. The appropriate treatment regimens in acute severe UC and the risk of perioperative use of biologics are unclear. As novel biologics and small molecules have been approved in Korea, we present the Korean guidelines for medical management of adult outpatients with moderate-to-severe UC and adult hospitalized patients with acute severe UC, focusing on biologics and small molecules.
6.Two Years of Experience and Methodology of Korean COVID-19 Living Clinical Practice Guideline Development
Miyoung CHOI ; Hyeon-Jeong LEE ; Su-Yeon YU ; Jimin KIM ; Jungeun PARK ; Seungeun RYOO ; Inho KIM ; Dong Ah PARK ; Young Kyung YOON ; Joon-Sung JOH ; Sunghoon PARK ; Ki Wook YUN ; Chi-Hoon CHOI ; Jae-Seok KIM ; Sue SHIN ; Hyun KIM ; Kyungmin HUH ; In-Seok JEONG ; Soo-Han CHOI ; Sung Ho HWANG ; Hyukmin LEE ; Dong Keon LEE ; Hwan Seok YONG ; Ho Kee YUM
Journal of Korean Medical Science 2023;38(23):e195-
Background:
In Korea, during the early phase of the coronavirus disease 2019 (COVID-19) pandemic, we responded to the uncertainty of treatments under various conditions, consistently playing catch up with the speed of evidence updates. Therefore, there was high demand for national-level evidence-based clinical practice guidelines for clinicians in a timely manner. We developed evidence-based and updated living recommendations for clinicians through a transparent development process and multidisciplinary expert collaboration.
Methods:
The National Evidence-based Healthcare Collaborating Agency (NECA) and the Korean Academy of Medical Sciences (KAMS) collaborated to develop trustworthy Korean living guidelines. The NECA-supported methodological sections and 8 professional medical societies of the KAMS worked with clinical experts, and 31 clinicians were involved annually. We developed a total of 35 clinical questions, including medications, respiratory/critical care, pediatric care, emergency care, diagnostic tests, and radiological examinations.
Results:
An evidence-based search for treatments began in March 2021 and monthly updates were performed. It was expanded to other areas, and the search interval was organized by a steering committee owing to priority changes. Evidence synthesis and recommendation review was performed by researchers, and living recommendations were updated within 3–4 months.
Conclusion
We provided timely recommendations on living schemes and disseminated them to the public, policymakers and various stakeholders using webpages and social media.Although the output was successful, there were some limitations. The rigor of development issues, urgent timelines for public dissemination, education for new developers, and spread of several new COVID-19 variants have worked as barriers. Therefore, we must prepare systematic processes and funding for future pandemics.
7.2022 Seoul Consensus on Clinical Practice Guidelines for Functional Constipation
Young Sin CHO ; Yoo Jin LEE ; Jeong Eun SHIN ; Hye-Kyung JUNG ; Seon-Young PARK ; Seung Joo KANG ; Kyung Ho SONG ; Jung-Wook KIM ; Hyun Chul LIM ; Hee Sun PARK ; Seong-Jung KIM ; Ra Ri CHA ; Ki Bae BANG ; Chang Seok BANG ; Sung Kyun YIM ; Seung-Bum RYOO ; Bong Hyeon KYE ; Woong Bae JI ; Miyoung CHOI ; In-Kyung SUNG ; Suck Chei CHOI ;
Journal of Neurogastroenterology and Motility 2023;29(3):271-305
Chronic constipation is one of the most common digestive diseases encountered in clinical practice. Constipation manifests as a variety of symptoms, such as infrequent bowel movements, hard stools, feeling of incomplete evacuation, straining at defecation, a sense of anorectal blockage during defecation, and use of digital maneuvers to assist defecation. During the diagnosis of chronic constipation, the Bristol Stool Form Scale, colonoscopy, and a digital rectal examination are useful for objective symptom evaluation and differential diagnosis of secondary constipation. Physiological tests for functional constipation have complementary roles and are recommended for patients who have failed to respond to treatment with available laxatives and those who are strongly suspected of having a defecatory disorder. As new evidence on the diagnosis and management of functional constipation emerged, the need to revise the previous guideline was suggested. Therefore, these evidence-based guidelines have proposed recommendations developed using a systematic review and meta-analysis of the treatment options available for functional constipation. The benefits and cautions of new pharmacological agents (such as lubiprostone and linaclotide) and conventional laxatives have been described through a meta-analysis. The guidelines consist of 34 recommendations, including 3 concerning the definition and epidemiology of functional constipation, 9 regarding diagnoses, and 22 regarding managements. Clinicians (including primary physicians, general health professionals, medical students, residents, and other healthcare professionals) and patients can refer to these guidelines to make informed decisions regarding the management of functional constipation.
8.Operational status of Korean emergency medical institutions in preparation for infectious disease outbreak after COVID-19 pandemic: 1 year later
Young Jun CHO ; Sungbae MOON ; Hyun Wook RYOO ; Jae Yun AHN ; Jinhui PAIK ; Eujene JUNG ; Joo JEONG ; Wook Jin CHOI ; Ki Jeong HONG
Journal of the Korean Society of Emergency Medicine 2023;34(6):568-585
Objective:
A regional pandemic may result in a crisis in providing emergency care to the community and disrupt emergency medical services. This study examined how the recent coronavirus disease 2019 pandemic impacted emergency department (ED) preparedness nationwide by describing the current ED operations.
Methods:
A cross-sectional survey was developed and distributed nationwide to emergency physicians. All 57 severe emergency care centers and 35 selected local emergency medical institutions nationwide were invited to participate. The survey consisted of basic ED information, infection guidelines, and operations for ED, preemptive pretriage area details, ED quarantine area details, cohort isolation and preemptive quarantine area, and difficulties or problems in treating infectious patients.
Results:
Forty-nine severe emergency care centers (86%) and 24 (68.6%) local emergency medical institutions answered the survey. Most EDs (95.9% and 91.7% of severe emergency care centers and local emergency medical institutions, respectively) operated under infection guidelines. In addition, 51% and 72.3% of preemptive pretriage areas in severe emergency care centers and local emergency medical institutions, respectively, placed doctors. Both negative and normal pressurized ED quarantine areas were more placed in severe emergency care centers (3 and 3 vs. 0.5 and 1 of severe emergency care centers and local emergency medical institutions, respectively). In severe emergency care centers, the preemptive quarantine areas were operated more than the cohort isolation areas (63.3% vs. 40.8%). Common difficulties expressed by EDs were delayed polymerase chain reaction test results (4.5 and 4.1 of severe emergency care centers and local emergency medical institutions, respectively) and a fear of infection with ED shutdown (4.4 and 4.1 of severe emergency care centers and local emergency medical institutions, respectively).
Conclusion
This study surveyed how ED care was changed by the pandemic and how current resources are redeployed nationwide. These results may be used as a basis for future ED pandemic preparedness.
9.Nationwide Survey for Current Status of Laboratory Diagnosis of Clostridioides difficile Infection in Korea
Hae-Sun CHUNG ; Jeong Su PARK ; Bo-Moon SHIN ; Hyeon Mi YOO ; Heejung KIM ; Jihyun CHO ; Chae Hoon LEE ; Nam Hee RYOO ; Jae-Seok KIM ; Jae-Woo CHUNG ; Ki Ho HONG ; You Sun KIM ; Young-Seok CHO
Journal of Korean Medical Science 2022;37(5):e38-
Background:
The interest in Clostridioides difficile infection (CDI) has increased, and the choice of assays became wider since the first national survey in Korea on CDI diagnosis in 2015. We conducted a survey of the domestic CDI assays with more varied questions to understand the current situation in Korea.
Methods:
In April 2018, about 50 questions on the current status of CDI assays and details on implementation and perceptions were written, and a survey questionnaire was administered to laboratory medicine specialists in 200 institutions.
Results:
One-hundred and fifty institutions responded to the questionnaire, of which 90 (60.0%) including one commercial laboratory, performed CDI assays. The toxin AB enzyme immunoassay (toxin AB EIA), nucleic acid amplification test (NAAT), and C. difficile culture, glutamate dehydrogenase assay, alone or in combination with other assays, were used in 75 (84.3%), 52 (58.4%), 35 (36.0%), and 23 (25.8%), respectively, and 65 (73.0%) institutions performed a combination of two or more assays. The sensitivity of toxin AB EIA was more negatively perceived, and that on specificity was more positively perceived. The perception of sensitivity and specificity of NAAT was mostly positive. Perception on the algorithm test projected it as useful but in need of countermeasures. Sixty-three (73.3%) institutions responded that they performed surveillance on CDI.
Conclusion
This study provides useful evidence on the current status of CDI laboratory diagnosis in Korea as well as on items that require improvement and is thought to aid in standardizing and improving the CDI laboratory diagnosis in Korea.
10.Nationwide “Pediatric Nutrition Day” survey on the nutritional status of hospitalized children in South Korea
Yoo Min LEE ; Eell RYOO ; Jeana HONG ; Ben KANG ; Byung-Ho CHOE ; Ji-Hyun SEO ; Ji Sook PARK ; Hyo-Jeong JANG ; Yoon LEE ; Eun Jae CHANG ; Ju Young CHANG ; Hae Jeong LEE ; Ju Young KIM ; Eun Hye LEE ; Hyun Jin KIM ; Ju-Young CHUNG ; You Jin CHOI ; So Yoon CHOI ; Soon Chul KIM ; Ki-Soo KANG ; Dae Yong YI ; Kyung Rye MOON ; Ji Hyuk LEE ; Yong Joo KIM ; Hye Ran YANG
Nutrition Research and Practice 2021;15(2):213-224
BACKGROUND/OBJECTIVES:
To evaluate the nutritional status and prevalence of malnutrition in hospitalized children at admission and during hospitalization in South Korea.
SUBJECTS/METHODS:
This first cross-sectional nationwide “Pediatric Nutrition Day (pNday)” survey was conducted among 872 hospitalized children (504 boys, 368 girls; 686 medical, 186 surgical) from 23 hospitals in South Korea. Malnutrition risk was screened using the Pediatric Yorkhill Malnutrition Score (PYMS) and the Screening Tool Risk on Nutritional status and Growth. Nutritional status was assessed by z-scores of weight-for-age for underweight, weight-for-height for wasting, and height-for-age for stunting as well as laboratory tests.
RESULTS:
At admission, of the 872 hospitalized children, 17.2% were underweight, and the prevalence of wasting and stunting was 20.2% and 17.3%, respectively. During hospitalization till pNday, 10.8% and 19.6% experienced weight loss and decreased oral intake, respectively.During the aforementioned period, fasting was more prevalent in surgical patients (7.5%) than in medical patients (1.6%) (P < 0.001). According to the PYMS, 34.3% and 30% of the children at admission and on pNday, respectively, had a high-risk of malnutrition, requiring consultation with the nutritional support team (NST). However, only 4% were actually referred to the NST during hospitalization.
CONCLUSIONS
Malnutrition was prevalent at admission and during hospitalization in pediatric patients, with many children experiencing weight loss and poor oral intake. To improve the nutritional status of hospitalized children, it is important to screen and identify all children at risk of malnutrition and refer malnourished patients to the multidisciplinary NST for proper nutritional interventions.

Result Analysis
Print
Save
E-mail